[
  {
    "ts": "2025-11-18T09:45:15+00:00",
    "headline": "Stifel Maintains Hold Rating on Vertex (VRTX), Keeps $445 Price Target",
    "summary": "Vertex Pharmaceuticals Incorporated (NASDAQ:VRTX) is one of the best gene-editing stocks to buy according to hedge funds. On November 10, Stifel maintained a Hold rating on Vertex Pharmaceuticals Incorporated (NASDAQ:VRTX). The firm also kept its price target at $445 for the stock. Stifel’s analysts referenced Vertex’s presentation of povetacicept (a dual BAFF/APRIL inhibitor) open-label Phase […]",
    "url": "https://finance.yahoo.com/news/stifel-maintains-hold-rating-vertex-094515901.html",
    "source": "Insider Monkey",
    "provider": "yfinance",
    "raw": {
      "id": "c9226120-d140-341b-9934-10755b483139",
      "content": {
        "id": "c9226120-d140-341b-9934-10755b483139",
        "contentType": "STORY",
        "title": "Stifel Maintains Hold Rating on Vertex (VRTX), Keeps $445 Price Target",
        "description": "",
        "summary": "Vertex Pharmaceuticals Incorporated (NASDAQ:VRTX) is one of the best gene-editing stocks to buy according to hedge funds. On November 10, Stifel maintained a Hold rating on Vertex Pharmaceuticals Incorporated (NASDAQ:VRTX). The firm also kept its price target at $445 for the stock. Stifel’s analysts referenced Vertex’s presentation of povetacicept (a dual BAFF/APRIL inhibitor) open-label Phase […]",
        "pubDate": "2025-11-18T09:45:15Z",
        "displayTime": "2025-11-18T09:45:15Z",
        "isHosted": true,
        "bypassModal": false,
        "previewUrl": null,
        "thumbnail": {
          "originalUrl": "https://media.zenfs.com/en/insidermonkey.com/ebfc00a4e36a86ae93bae37394969574",
          "originalWidth": 300,
          "originalHeight": 300,
          "caption": "tifel Maintains Hold Rating on Vertex (VRTX), Keeps $445 Price Target",
          "resolutions": [
            {
              "url": "https://s.yimg.com/uu/api/res/1.2/OrUjEhTQ558OAB4v1CuhoA--~B/aD0zMDA7dz0zMDA7YXBwaWQ9eXRhY2h5b24-/https://media.zenfs.com/en/insidermonkey.com/ebfc00a4e36a86ae93bae37394969574.cf.webp",
              "width": 300,
              "height": 300,
              "tag": "original"
            },
            {
              "url": "https://s.yimg.com/uu/api/res/1.2/0loC6Itwxz._frgmtnABlQ--~B/Zmk9c3RyaW07aD0xMjg7dz0xNzA7YXBwaWQ9eXRhY2h5b24-/https://media.zenfs.com/en/insidermonkey.com/ebfc00a4e36a86ae93bae37394969574.cf.webp",
              "width": 170,
              "height": 128,
              "tag": "170x128"
            }
          ]
        },
        "provider": {
          "displayName": "Insider Monkey",
          "url": "http://www.insidermonkey.com"
        },
        "canonicalUrl": {
          "url": "https://finance.yahoo.com/news/stifel-maintains-hold-rating-vertex-094515901.html",
          "site": "finance",
          "region": "US",
          "lang": "en-US"
        },
        "clickThroughUrl": {
          "url": "https://finance.yahoo.com/news/stifel-maintains-hold-rating-vertex-094515901.html",
          "site": "finance",
          "region": "US",
          "lang": "en-US"
        },
        "metadata": {
          "editorsPick": false
        },
        "finance": {
          "stockTickers": [
            {
              "symbol": "VRTX"
            }
          ],
          "premiumFinance": {
            "isPremiumNews": false,
            "isPremiumFreeNews": false
          }
        },
        "storyline": null
      }
    }
  },
  {
    "ts": "2025-11-18T14:00:04+00:00",
    "headline": "Vertex Pharmaceuticals Incorporated (VRTX) is Attracting Investor Attention: Here is What You Should Know",
    "summary": "Vertex (VRTX) has received quite a bit of attention from Zacks.com users lately. Therefore, it is wise to be aware of the facts that can impact the stock's prospects.",
    "url": "https://finance.yahoo.com/news/vertex-pharmaceuticals-incorporated-vrtx-attracting-140004066.html",
    "source": "Zacks",
    "provider": "yfinance",
    "raw": {
      "id": "4002b35a-49c2-3a91-846a-89011d62e79d",
      "content": {
        "id": "4002b35a-49c2-3a91-846a-89011d62e79d",
        "contentType": "STORY",
        "title": "Vertex Pharmaceuticals Incorporated (VRTX) is Attracting Investor Attention: Here is What You Should Know",
        "description": "",
        "summary": "Vertex (VRTX) has received quite a bit of attention from Zacks.com users lately. Therefore, it is wise to be aware of the facts that can impact the stock's prospects.",
        "pubDate": "2025-11-18T14:00:04Z",
        "displayTime": "2025-11-18T14:00:04Z",
        "isHosted": true,
        "bypassModal": false,
        "previewUrl": null,
        "thumbnail": {
          "originalUrl": "https://media.zenfs.com/en/zacks.com/8442d24e11d454aa89061259a9714d43",
          "originalWidth": 900,
          "originalHeight": 601,
          "caption": "",
          "resolutions": [
            {
              "url": "https://s.yimg.com/uu/api/res/1.2/E8QyPjKtRaOQj91uVCJHQA--~B/aD02MDE7dz05MDA7YXBwaWQ9eXRhY2h5b24-/https://media.zenfs.com/en/zacks.com/8442d24e11d454aa89061259a9714d43.cf.webp",
              "width": 900,
              "height": 601,
              "tag": "original"
            },
            {
              "url": "https://s.yimg.com/uu/api/res/1.2/hjTg63kWHBfUb8JQmmr1kg--~B/Zmk9c3RyaW07aD0xMjg7dz0xNzA7YXBwaWQ9eXRhY2h5b24-/https://media.zenfs.com/en/zacks.com/8442d24e11d454aa89061259a9714d43.cf.webp",
              "width": 170,
              "height": 128,
              "tag": "170x128"
            }
          ]
        },
        "provider": {
          "displayName": "Zacks",
          "url": "http://www.zacks.com/"
        },
        "canonicalUrl": {
          "url": "https://finance.yahoo.com/news/vertex-pharmaceuticals-incorporated-vrtx-attracting-140004066.html",
          "site": "finance",
          "region": "US",
          "lang": "en-US"
        },
        "clickThroughUrl": {
          "url": "https://finance.yahoo.com/news/vertex-pharmaceuticals-incorporated-vrtx-attracting-140004066.html",
          "site": "finance",
          "region": "US",
          "lang": "en-US"
        },
        "metadata": {
          "editorsPick": false
        },
        "finance": {
          "stockTickers": [
            {
              "symbol": "VRTX"
            },
            {
              "symbol": "^SPX"
            }
          ],
          "premiumFinance": {
            "isPremiumNews": false,
            "isPremiumFreeNews": false
          }
        },
        "storyline": null
      }
    }
  },
  {
    "ts": "2025-11-18T12:54:36+00:00",
    "headline": "Vertex Pharmaceuticals Stock: Analyst Estimates & Ratings",
    "summary": "Vertex Pharmaceuticals’ stock has trailed behind the broader market, but analysts are still taking a moderately bullish stance about its prospects.",
    "url": "https://www.barchart.com/story/news/36180165/vertex-pharmaceuticals-stock-analyst-estimates-ratings",
    "source": "Barchart",
    "provider": "yfinance",
    "raw": {
      "id": "c2b691b1-dcf2-3cd3-9383-745dbd7c1a10",
      "content": {
        "id": "c2b691b1-dcf2-3cd3-9383-745dbd7c1a10",
        "contentType": "STORY",
        "title": "Vertex Pharmaceuticals Stock: Analyst Estimates & Ratings",
        "description": "",
        "summary": "Vertex Pharmaceuticals’ stock has trailed behind the broader market, but analysts are still taking a moderately bullish stance about its prospects.",
        "pubDate": "2025-11-18T12:54:36Z",
        "displayTime": "2025-11-18T12:54:36Z",
        "isHosted": true,
        "bypassModal": false,
        "previewUrl": null,
        "thumbnail": {
          "originalUrl": "https://media.zenfs.com/en/barchart_com_477/c67ca0ce21e47cc43676e5a55d771ea0",
          "originalWidth": 1000,
          "originalHeight": 666,
          "caption": "Vertex Pharmaceuticals, Inc_ HQ in Boston-by Tada Images via Shuttershock",
          "resolutions": [
            {
              "url": "https://s.yimg.com/uu/api/res/1.2/Shb7JdZjS3KjsEy4OVFfew--~B/aD02NjY7dz0xMDAwO2FwcGlkPXl0YWNoeW9u/https://media.zenfs.com/en/barchart_com_477/c67ca0ce21e47cc43676e5a55d771ea0.cf.webp",
              "width": 1000,
              "height": 666,
              "tag": "original"
            },
            {
              "url": "https://s.yimg.com/uu/api/res/1.2/EMGmPiWDsIHqjC0QyY.H8Q--~B/Zmk9c3RyaW07aD0xMjg7dz0xNzA7YXBwaWQ9eXRhY2h5b24-/https://media.zenfs.com/en/barchart_com_477/c67ca0ce21e47cc43676e5a55d771ea0.cf.webp",
              "width": 170,
              "height": 128,
              "tag": "170x128"
            }
          ]
        },
        "provider": {
          "displayName": "Barchart",
          "url": "https://www.barchart.com/"
        },
        "canonicalUrl": {
          "url": "https://www.barchart.com/story/news/36180165/vertex-pharmaceuticals-stock-analyst-estimates-ratings",
          "site": "finance",
          "region": "US",
          "lang": "en-US"
        },
        "clickThroughUrl": {
          "url": "https://finance.yahoo.com/news/vertex-pharmaceuticals-stock-analyst-estimates-125436973.html",
          "site": "finance",
          "region": "US",
          "lang": "en-US"
        },
        "metadata": {
          "editorsPick": false
        },
        "finance": {
          "stockTickers": [
            {
              "symbol": "VRTX"
            },
            {
              "symbol": "XLV"
            },
            {
              "symbol": "^SPX"
            }
          ],
          "premiumFinance": {
            "isPremiumNews": false,
            "isPremiumFreeNews": false
          }
        },
        "storyline": null
      }
    }
  },
  {
    "ts": "2025-11-18T18:16:20+00:00",
    "headline": "A Look at Vertex Pharmaceuticals’s Valuation Following Promising Kidney Trial Updates and New FDA Designations",
    "summary": "Vertex Pharmaceuticals (VRTX) has drawn attention with new data from its RUBY-3 trial, showing that povetacicept has achieved meaningful results in two kidney diseases. The recent FDA designations further highlight ongoing momentum in its late-stage pipeline. See our latest analysis for Vertex Pharmaceuticals. The latest pivotal trial results and fresh FDA recognition appear to have injected new optimism into Vertex Pharmaceuticals, with the stock posting an impressive 11% share price return...",
    "url": "https://finance.yahoo.com/news/look-vertex-pharmaceuticals-valuation-following-181620808.html",
    "source": "Simply Wall St.",
    "provider": "yfinance",
    "raw": {
      "id": "c4a79323-ccfa-3d88-885f-71119806d154",
      "content": {
        "id": "c4a79323-ccfa-3d88-885f-71119806d154",
        "contentType": "STORY",
        "title": "A Look at Vertex Pharmaceuticals’s Valuation Following Promising Kidney Trial Updates and New FDA Designations",
        "description": "",
        "summary": "Vertex Pharmaceuticals (VRTX) has drawn attention with new data from its RUBY-3 trial, showing that povetacicept has achieved meaningful results in two kidney diseases. The recent FDA designations further highlight ongoing momentum in its late-stage pipeline. See our latest analysis for Vertex Pharmaceuticals. The latest pivotal trial results and fresh FDA recognition appear to have injected new optimism into Vertex Pharmaceuticals, with the stock posting an impressive 11% share price return...",
        "pubDate": "2025-11-18T18:16:20Z",
        "displayTime": "2025-11-18T18:16:20Z",
        "isHosted": true,
        "bypassModal": false,
        "previewUrl": null,
        "thumbnail": {
          "originalUrl": "https://media.zenfs.com/en/simply_wall_st__316/be31617c737d47553e0bc442fa8fa6d9",
          "originalWidth": 1194,
          "originalHeight": 432,
          "caption": "",
          "resolutions": [
            {
              "url": "https://s.yimg.com/uu/api/res/1.2/ihFoSuY9PLXURl2kI_sV.w--~B/aD00MzI7dz0xMTk0O2FwcGlkPXl0YWNoeW9u/https://media.zenfs.com/en/simply_wall_st__316/be31617c737d47553e0bc442fa8fa6d9.cf.webp",
              "width": 1194,
              "height": 432,
              "tag": "original"
            },
            {
              "url": "https://s.yimg.com/uu/api/res/1.2/bIz6sh0rX4c7ACsVP8z51w--~B/Zmk9c3RyaW07aD0xMjg7dz0xNzA7YXBwaWQ9eXRhY2h5b24-/https://media.zenfs.com/en/simply_wall_st__316/be31617c737d47553e0bc442fa8fa6d9.cf.webp",
              "width": 170,
              "height": 128,
              "tag": "170x128"
            }
          ]
        },
        "provider": {
          "displayName": "Simply Wall St.",
          "url": "https://simplywall.st/"
        },
        "canonicalUrl": {
          "url": "https://finance.yahoo.com/news/look-vertex-pharmaceuticals-valuation-following-181620808.html",
          "site": "finance",
          "region": "US",
          "lang": "en-US"
        },
        "clickThroughUrl": {
          "url": "https://finance.yahoo.com/news/look-vertex-pharmaceuticals-valuation-following-181620808.html",
          "site": "finance",
          "region": "US",
          "lang": "en-US"
        },
        "metadata": {
          "editorsPick": false
        },
        "finance": {
          "stockTickers": [
            {
              "symbol": "VRTX"
            }
          ],
          "premiumFinance": {
            "isPremiumNews": false,
            "isPremiumFreeNews": false
          }
        },
        "storyline": null
      }
    }
  }
]